Immunofluorescence analysis of Cyclin B1 was performed using 70% confluent log phase HT-29 cells treated 100 ng of Nocodazole for 16 hours. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with Cyclin B1 Mouse (V152) Monoclonal Antibody (Product # MA5-13128) at 2µg/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjµgate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e is untreated cell with no signal. Panel f represents control cells with no primary antibody to assess background. The images were captured at 60X magnification..
|Tested species reactivity||Hamster, Human, Mouse|
|Published species reactivity||Rat, Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Hamster cyclin B1 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13128 targets Cyclin B1 in FACS, IHC (P), and WB applications and shows reactivity with Hamster and Human samples.
The MA5-13128 immunogen is hamster cyclin B1 protein.
In mammals, cyclin B associates with inactive p34cdc2. Cyclin Bp34cdc2 plays a critical role in G2 to M transition.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Aurora kinase A is not involved in CPEB1 phosphorylation and cyclin B1 mRNA polyadenylation during meiotic maturation of porcine oocytes.
MA5-13128 was used in western blot to determine meiotic maturation of porcine oocytes and how aurora kinase A is not involved in CPEB1 phosphorylation and cyclin B1 mRNA polyadenylation
|Komrskova P,Susor A,Malik R,Prochazkova B,Liskova L,Supolikova J,Hladky S,Kubelka M||PloS one (9:null)||2014|
The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
MA5-13128 was used in western blot to study the effects of the CDK inhibitor seliciclib on the control of entry into mitosis using cDNA microarrays to assess gene expression
|Whittaker SR,Te Poele RH,Chan F,Linardopoulos S,Walton MI,Garrett MD,Workman P||Cell cycle (Georgetown, Tex.) (6:3114)||2007|
Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage.
MA5-13128 was used in western blot to study the role of Huwe1 in regulating cdc6 stability after cell damage
|Hall JR,Kow E,Nevis KR,Lu CK,Luce KS,Zhong Q,Cook JG||Molecular biology of the cell (18:3340)||2007|
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
MA5-13128 was used in western blot to study the pharmacokinetics and pharmacodynamics of three tri-substituted aminopurine Cdk inhibitors in a model of colon carcinoma
|Raynaud FI,Whittaker SR,Fischer PM,McClue S,Walton MI,Barrie SE,Garrett MD,Rogers P,Clarke SJ,Kelland LR,Valenti M,Brunton L,Eccles S,Lane DP,Workman P||Clinical cancer research : an official journal of the American Association for Cancer Research (11:4875)||2005|
Citron kinase is a cell cycle-dependent, nuclear protein required for G2/M transition of hepatocytes.
MA5-13128 was used in western blot to investigate the role of citron kinase in hepatocyte cell cycle progression
|Liu H,Di Cunto F,Imarisio S,Reid LM||The Journal of biological chemistry (278:2541)||2003|
Mitotic cell cycle proteins increase in podocytes despite lack of proliferation.
MA5-13128 was used in western blot to study the increase in mitotic cell cycle protein in podocyes in the absence of increased proliferation
|Petermann AT,Pippin J,Hiromura K,Monkawa T,Durvasula R,Couser WG,Kopp J,Shankland SJ||Kidney international (63:113)||2003|
Cellular distributions of molecules with altered expression specific to thyroid proliferative lesions developing in a rat thyroid carcinogenesis model.
MA5-13128 was used in immunohistochemistry to identify molecules whose expression is altered in thyroid lesions in a rat model of thyroid carconogenesis
|Woo GH,Takahashi M,Inoue K,Fujimoto H,Igarashi K,Kanno J,Hirose M,Nishikawa A,Shibutani M||Cancer science (100:617)||2009|
Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.
MA5-13128 was used in immunohistochemistry to study the prognostic value of the expression of a range of cell cycle regulatory proteins in gastrointestinal stromal tumors
|Nakamura N,Yamamoto H,Yao T,Oda Y,Nishiyama K,Imamura M,Yamada T,Nawata H,Tsuneyoshi M||Human pathology (36:828)||2005|
Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity.
MA5-13128 was used in immunohistochemistry to study the correlation between ALK protein expression and the proliferative capacity of anaplastic large-cell lymphomas
|Leoncini L,Lazzi S,Scano D,Mura A,Onida A,Massarelli G,Tosi P,Barbini P,Cevenini G,Massai MR,Pileri S,Falini B,Giordano A,Kraft R,Laissue JA,Cottier H||International journal of cancer (86:777)||2000|
Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control.
MA5-13128 was used in immunohistochemistry to study the expression and role of retinoblastoma protein/p107 and retinoblastoma protein2/p130 in non-Hodgkin's lymphoma
|Leoncini L,Bellan C,Cossu A,Claudio PP,Lazzi S,Cinti C,Cevenini G,Megha T,Laurini L,Luzi P,Orcioni GF,Piccioli M,Pileri S,Giardino C,Tosi P,Giordano A||Clinical cancer research : an official journal of the American Association for Cancer Research (5:4065)||1999|
Expression of p34(cdc2) and cyclins A and B compared to other proliferative features of non-Hodgkin's lymphomas: a multivariate cluster analysis.
MA5-13128 was used in immunohistochemistry to perform a multivariate cluster analysis of p34(cdc2), cyclin A and cyclin B expresssion in non-Hodgkin's lymphoma
|Leoncini L,Cossu A,Megha T,Bellan C,Lazzi S,Luzi P,Tosi P,Barbini P,Cevenini G,Pileri S,Giordano A,Kraft R,Laissue JA,Cottier H||International journal of cancer (83:203)||1999|
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.
MA5-13128 was used in flow cytometry to examine the allogenic glioma cells for the generation of therapeutic vaccines or cellular therapy
|Zhang JG,Eguchi J,Kruse CA,Gomez GG,Fakhrai H,Schroter S,Ma W,Hoa N,Minev B,Delgado C,Wepsic HT,Okada H,Jadus MR||Clinical cancer research : an official journal of the American Association for Cancer Research (13:566)||2007|
Kinetics of endomitosis in primary murine megakaryocytes.
MA5-13128 was used in flow cytometry to investigate the mechanism of endomitosis in primary murine megakaryocytes
|Carow CE,Fox NE,Kaushansky K||Journal of cellular physiology (188:291)||2001|